SCHEMBL23409262

SCHEMBL23409262

CC(c1ccccc1)c1nccn1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.37
KDM4A O75164 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
CYP2D6 P10635 1/20 0.36
REN P00797 1/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 1/20 0.35
BCHE P06276 1/20 0.35
HTR1A P08908 1/20 0.35
ADRB3 P13945 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
DRD3 P35462 1/20 0.35
HTR2B P41595 1/20 0.35
HTR6 P50406 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28668028 0.82 TTR (0.39) KDM4ESMN1; SMN2POLBKMT2ACYP2D6
SCHEMBL1573467 0.78 ADRA2A (0.38) KDM4ESMN1; SMN2KMT2ACYP2D6ALDH1A1
Hydrochloric Acid SCHEMBL28364110 0.75 SMN1; SMN2 (0.44) KDM4ESMN1; SMN2KMT2AALDH1A1
Bromide SCHEMBL28364106 0.75 SMN1; SMN2 (0.41) KDM4ESMN1; SMN2KMT2AALDH1A1
Hydrochloric Acid SCHEMBL29054527 0.75 KDM4E (0.65) KDM4ESMN1; SMN2KMT2ACYP2D6ALDH1A1
SCHEMBL27625281 0.73 SMN1; SMN2 (0.43) KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4669258 0.73 KMT2A (0.48) KDM4ESMN1; SMN2KMT2ACYP2D6ALDH1A1
SCHEMBL1740334 0.71 SMN1; SMN2 (0.41) KDM4ESMN1; SMN2KMT2A
SCHEMBL698829 0.70 NPC1 (0.39) KDM4ESMN1; SMN2KMT2ACYP2D6CYP1A2
SCHEMBL27750528 0.70 KDM4E (0.46) KDM4ESMN1; SMN2POLBKMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737444-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS Gilead Sciences, Inc. (US) 2026-05-06 EP disclosed
US-12410146-B2 Processes and intermediates for preparing MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 US disclosed
EP-4484435-A2 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS Gilead Sciences, Inc. (US) 2025-01-01 EP disclosed
EP-4065567-B1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES INC (US) 2024-09-11 EP disclosed
US-20240109851-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. 2024-04-04 US disclosed
US-11760736-B2 Processes and intermediates for preparing MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2023-09-19 US disclosed
US-20230013713-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. 2023-01-19 US disclosed
EP-4065567-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. (US) 2022-10-05 EP disclosed
US-11325891-B2 Processes and intermediates for preparing MCL1 inhibitors GILEAD SCIENCES, INC. (US) 2022-05-10 US disclosed
US-20210179570-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. 2021-06-17 US disclosed
WO-2021108254-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410146-B2 Processes and intermediates for preparing MCL1 inhibitors MCL1, BAK1, BCL3 KDM4E 1483/4885SMN1; SMN2 1917/4885POLB 935/4885
US-11760736-B2 Processes and intermediates for preparing MCL1 inhibitors MCL1, BAK1, BCL3 KDM4E 1483/4885SMN1; SMN2 1917/4885POLB 935/4885
US-20210179570-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS MCL1, BAK1, BCL3 KDM4E 1483/4885SMN1; SMN2 1917/4885POLB 935/4885
US-11325891-B2 Processes and intermediates for preparing MCL1 inhibitors MCL1, BAK1, BCL3 KDM4E 1483/4885SMN1; SMN2 1917/4885POLB 935/4885
US-20240109851-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS MCL1, BAK1, BCL3 KDM4E 1483/4885SMN1; SMN2 1917/4885POLB 935/4885
US-20230013713-A1 PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS MCL1, BAK1, BCL3 KDM4E 1483/4885SMN1; SMN2 1917/4885POLB 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.